Lexaria Bioscience Corp. announced on April 2, 2025, that dosing has begun as scheduled in its human study GLP-1-H25-5. This study is comparing oral DehydraTECH-liraglutide to injected Saxenda®-branded liraglutide.
The study will investigate the pharmacokinetics and safety of Lexaria's oral formulation. This advancement follows positive findings from a 12-week rodent study reported on November 20, 2024, where oral DehydraTECH-liraglutide showed a 5.88% weight reduction and an 11.54% blood sugar reduction compared to baseline.
Initiating this head-to-head human study is a critical step in demonstrating the potential of DehydraTECH to provide an effective oral alternative to injectable liraglutide. The results are expected to further support Lexaria's strategic pursuit of the world's first orally-dosed liraglutide.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.